Creatinine clearance · Adults with chronic kidney disease not requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Creatinine clearance: WMD -1.68 (95% CI -6.92 to 3.56), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
WMD -1.68 [-6.92, 3.56]
4 studies
GRADE not reported
Risk of hyperphosphataemia · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Risk of hyperphosphataemia: RR 1.57 (95% CI 0.97 to 2.54), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Fracture · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Fractures: RR 1.00 (95% CI 0.06 to 15.41), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
RR 1.00 [0.06, 15.41]
4 studies
GRADE not reported
Hypercalcaemia · Adults with chronic kidney disease not requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Risk of hypercalcaemia: RR 3.04 (95% CI 1.17 to 7.90), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review
Parathyroid hormone · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Parathyroid hormone: WMD -196.05 (95% CI -298.43 to -93.66), statistically significant. Umbrella review outcome-level evidence grade: Probable.
1 finding from 1 review
Risk of requiring dialysis · Adults with chronic kidney disease not requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Risk of requiring dialysis: RR 0.76 (95% CI 0.36 to 1.62), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Parathyroid hormone · Adults with chronic kidney disease not requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Parathyroid hormone: WMD -49.34 (95% CI -85.70 to -12.97), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review
Vascular calcification · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Vascular calcification: RR 1.09 (95% CI 0.45 to 2.67), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
All‐cause mortality · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Mortality: RR 1.34 (95% CI 0.34 to 5.24), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Alkaline phosphatase · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Alkaline phosphatase: WMD -27.35 (95% CI -50.69 to -4.01), statistically significant. Umbrella review outcome-level evidence grade: Suggestive.
1 finding from 1 review
Parathyroidectomy · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Parathyroidectomy: RR 0.82 (95% CI 0.05 to 12.47), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Alkaline phosphatase · Adults with chronic kidney disease not requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Alkaline phosphatase: WMD -21.81 (95% CI -40.39 to 3.22), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Risk of hyperphosphataemia · Adults with chronic kidney disease not requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Risk of hyperphosphataemia: RR 1.58 (95% CI 0.47 to 5.30), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Bone pain · Adults with chronic kidney disease requiring dialysis
Meta-analysis of randomised trials of vitamin D supplementation for Bone pain: RR 0.29 (95% CI 0.03 to 2.63), not statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
Maternal death · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in maternal mortality compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Maternal morbidity (diarrhoea, respiratory infections, fever) · women in the postpartum period
1 finding from 1 review
Adverse effects on women: abdominal cramps · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in maternal adverse effects after administration: abdominal pain compared with placebo or no treatment (low certainty).
1 finding from 1 review
Maternal breast milk retinol concentration · women in the postpartum period
1 finding from 1 review
Change in Infant Mortality Rate per 1000 live births1 · women in the postpartum period
Vitamin A supplementation (200,000 to 400,000 IU) showed no clear difference in infant mortality compared with placebo or no treatment (low certainty).
1 finding from 1 review
Infant morbidity (gastroenteritis) · women in the postpartum period
It is very uncertain whether vitamin A supplementation (200,000 to 400,000 IU) changes infant morbidity (gastroenteritis) compared with placebo or no treatment (very low certainty).
1 finding from 1 review